Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide + ADT + abiraterone neoadjuvant therapy for localized high-risk or locally advanced prostate cancer
ChiCTR2400091681Phase 4Recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rezvilutamide, abiraterone, degarelix and prednisone in prostate cancer (PCa), sponsored by Xijing Hospital. Primary endpoint: Positive surgical margin rate. Started Nov 2024; status: recruiting.
02
Drugs
rezvilutamideabirateronedegarelixprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400091681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091681.